Fabrinet to Present at J.P. Morgan Conference
Get Alerts FN Hot Sheet
Join SI Premium – FREE
BANGKOK, May 06, 2025 (GLOBE NEWSWIRE) -- Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced that its management will present at the 53rd Annual J.P. Morgan Global Technology, Media and Communications Conference in Boston, MA.
The Fabrinet presentation is scheduled for Thursday, May 15, 2025 at 10:00 a.m. EDT (7:00 a.m. PDT). A live webcast, as well as a replay, will be accessible at https://investor.fabrinet.com/.
About Fabrinet
Fabrinet is a leading provider of advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and subsystems, automotive components, medical devices, industrial lasers and sensors. Fabrinet offers a broad range of advanced optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, advanced packaging, integration, final assembly and testing. Fabrinet focuses on production of high complexity products in any mix and any volume. Fabrinet maintains engineering and manufacturing resources and facilities in Thailand, the United States of America, the People’s Republic of China and Israel. For more information visit: https://fabrinet.com/.
SOURCE: Fabrinet
Investor Contact:
Garo Toomajanian
[email protected]
Source: Fabrinet
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hertz Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Hertz Global Holdings, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit
- University of Miami launches Master of Science in Marketing
- Nearly two-thirds of Nephrologists Cite Limited Treatment Options as Alport Syndrome’s Greatest Challenge Amid Growing Pipeline Interest, According to Spherix Global Insights
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share